APYX Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -6.47% compared to Apyx Medical Corp.'s net margin of -13.47%. Apyx Medical Corp.'s return on equity of -104.09% beat Accuray, Inc.'s return on equity of -60.6%.

Apyx Medical Corp. has a consensus price target of $6.40, signalling upside risk potential of 73.91%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 507.99%. Given that Accuray, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Accuray, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.542, which suggesting that the stock is 54.238% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.317, suggesting its more volatile than the S&P 500 by 31.653%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $19.2M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Apyx Medical Corp.'s net income of -$1.2M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 2.88x versus 0.11x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -6.47% compared to Apyx Medical Corp.'s net margin of -10.21%. Apyx Medical Corp.'s return on equity of -104.09% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.

Apyx Medical Corp. has a consensus price target of $6.40, signalling upside risk potential of 73.91%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.42 which suggests that it could grow by 125.45%. Given that Alphatec Holdings, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Alphatec Holdings, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.542, which suggesting that the stock is 54.238% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.117, suggesting its more volatile than the S&P 500 by 11.658%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $19.2M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Apyx Medical Corp.'s net income of -$1.2M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 2.88x versus 2.05x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LeMaitre Vascular, Inc. has a net margin of -6.47% compared to Apyx Medical Corp.'s net margin of 24.18%. Apyx Medical Corp.'s return on equity of -104.09% beat LeMaitre Vascular, Inc.'s return on equity of 15.86%.

Apyx Medical Corp. has a consensus price target of $6.40, signalling upside risk potential of 73.91%. On the other hand LeMaitre Vascular, Inc. has an analysts' consensus of $111.22 which suggests that it could grow by 2.52%. Given that Apyx Medical Corp. has higher upside potential than LeMaitre Vascular, Inc., analysts believe Apyx Medical Corp. is more attractive than LeMaitre Vascular, Inc..

Apyx Medical Corp. has a beta of 1.542, which suggesting that the stock is 54.238% more volatile than S&P 500. In comparison LeMaitre Vascular, Inc. has a beta of 0.672, suggesting its less volatile than the S&P 500 by 32.831%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular, Inc. offers a yield of 0.79% to investors and pays a quarterly dividend of $0.25 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. LeMaitre Vascular, Inc. pays out 31.77% of its earnings as a dividend. LeMaitre Vascular, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Apyx Medical Corp. quarterly revenues are $19.2M, which are smaller than LeMaitre Vascular, Inc. quarterly revenues of $64.5M. Apyx Medical Corp.'s net income of -$1.2M is lower than LeMaitre Vascular, Inc.'s net income of $15.6M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while LeMaitre Vascular, Inc.'s PE ratio is 42.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 2.88x versus 10.08x for LeMaitre Vascular, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -6.47% compared to Apyx Medical Corp.'s net margin of -417.92%. Apyx Medical Corp.'s return on equity of -104.09% beat Plus Therapeutics, Inc.'s return on equity of --.

Apyx Medical Corp. has a consensus price target of $6.40, signalling upside risk potential of 73.91%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Apyx Medical Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Apyx Medical Corp..

Apyx Medical Corp. has a beta of 1.542, which suggesting that the stock is 54.238% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Apyx Medical Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apyx Medical Corp. quarterly revenues are $19.2M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Apyx Medical Corp.'s net income of -$1.2M is higher than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Apyx Medical Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical Corp. is 2.88x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.